Drug intelligence / Profile preview

ENGI-006

Development stage: Discontinued
Lead developer: Engimmune Therapeutics

Overview

**ENGI-006** is an investigational therapeutic candidate developed by Engimmune Therapeutics AG for oncology indications. It targets **solid tumors**, but specific details on its mechanism of action, modality, or biological target are not publicly disclosed in available sources. The program has been **discontinued**, with no further information on clinical trials, development phase, or precise indications beyond solid tumors.[5]

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on ENGI-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENGI-006.

Explore the full profile